Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, University Heidelberg, Heidelberg, Germany.
Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Oncoimmunology. 2021 Aug 10;10(1):1962135. doi: 10.1080/2162402X.2021.1962135. eCollection 2021.
Various reports have pointed out the potential of cytokines as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDA). Nonetheless, the evidence is contradictory and the role of chronic inflammation and relationship between circulatory and corresponding tumoral cytokine levels remain elusive. Utilizing a broad array of cytokines, we identified two opposing parameters: serum levels of interleukin 2 (IL2) and macrophage migration inhibitory factor (MIF) are diagnostic and prognostic factors. While low IL2 levels are associated with PDA, they also relate to a favorable prognosis of patients. In contrast, high MIF levels are associated with PDA and simultaneously related to an unfavorable outcome. MIF levels are associated with the intratumoral density of M2 macrophages (CD163). Focusing on the tumor-to-serum gradient, we unveiled a different pattern of compartmental cytokine expression between IL2 and MIF. Our findings indicate that an extra-tumoral source of IL2 exists in PDA patients leading to increased detectability in the circulatory system. In case of MIF, the tumor microenvironment is presumably the main site of production and thereby reflected by serum measurements. Taken together, our study describes IL2 and MIF levels as biomarker candidates for diagnosis and prognosis of PDA, highlighting the need for compartmental cytokine analyses. From the perspective of tumor immunobiology, we identify multiple inflammatory states (proposed as types I-III) and see that systemic chronic dysregulation, independent of tumor microenvironment, can be measured and is a possible tool for stratification. Thus, direct correlation of local cytokine levels to peripheral blood levels needs to be regarded with caution.
各种报告指出细胞因子作为胰腺导管腺癌 (PDA) 的诊断和预后生物标志物的潜力。然而,证据相互矛盾,慢性炎症的作用和循环与相应肿瘤细胞因子水平之间的关系仍然难以捉摸。利用广泛的细胞因子,我们确定了两个相反的参数:白细胞介素 2 (IL2) 和巨噬细胞移动抑制因子 (MIF) 的血清水平是诊断和预后因素。虽然低 IL2 水平与 PDA 相关,但它们也与患者的有利预后有关。相比之下,高 MIF 水平与 PDA 相关,同时与不利的结果相关。MIF 水平与肿瘤内 M2 巨噬细胞 (CD163) 的密度有关。关注肿瘤与血清之间的梯度,我们揭示了 IL2 和 MIF 之间细胞因子表达的不同模式。我们的研究结果表明,PDA 患者存在 IL2 的肿瘤外来源,导致其在循环系统中检测到的增加。对于 MIF,肿瘤微环境可能是主要的产生部位,因此通过血清测量可以反映出来。总的来说,我们的研究将 IL2 和 MIF 水平描述为 PDA 诊断和预后的生物标志物候选物,强调了细胞因子分区分析的必要性。从肿瘤免疫生物学的角度来看,我们确定了多种炎症状态(拟议为 I-III 型),并看到系统慢性失调,独立于肿瘤微环境,可以被测量,并可能成为分层的工具。因此,需要谨慎看待局部细胞因子水平与外周血水平的直接相关性。